CD19-CART (PD-1 knockdown, Unicar-Therapy Bio-medicine Technology)

程序死亡受体1敲减的靶向CD19嵌合抗原受体工程化T细胞

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCD19-CART (PD-1 knockdown, Unicar-Therapy Bio-medicine Technology)

Drug Alias Name程序死亡受体1敲减的靶向CD19嵌合抗原受体工程化T细胞注射液

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusIND

Highest Status in ChinaIND

Originator CompaniesShanghai Unicar-Therapy Bio-Medicine Technology Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Unicar-Therapy Bio-Medicine Technology Co Ltd

Inactive CompaniesN/A

Active IndicationsLymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A